Entheon Biomedical Corp
CNSX:ENBI
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.07
0.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Entheon Biomedical Corp
Entheon Biomedical Corp. is a biotechnology company, which engages in developing and commercializing dimethyltryptamine based psychedelic therapeutic products. The company is headquartered in Coquitlam, British Columbia. The company went IPO on 2018-05-03. The firm focuses on developing a portfolio of Dimethyltryptamine (DMT) based psychedelic therapeutic products for treating addiction and substance use disorders. The Company’s DMT is advancing and sustaining new models of psychedelic-assisted therapy. The firm is developing a combination of genetic and predictive data analysis to ensure the safest psychedelic treatment possible. The firm is also developing a predictive biomarker response platform in partnership with Divergence NeuroTech. Its biomarker platform is artificial intelligence and machine learning and prescribes suitable psychedelic treatments and provides real-time feedback during a psychedelic event, and informs the development of a post-therapy system of patient-specific support.
Entheon Biomedical Corp. is a biotechnology company, which engages in developing and commercializing dimethyltryptamine based psychedelic therapeutic products. The company is headquartered in Coquitlam, British Columbia. The company went IPO on 2018-05-03. The firm focuses on developing a portfolio of Dimethyltryptamine (DMT) based psychedelic therapeutic products for treating addiction and substance use disorders. The Company’s DMT is advancing and sustaining new models of psychedelic-assisted therapy. The firm is developing a combination of genetic and predictive data analysis to ensure the safest psychedelic treatment possible. The firm is also developing a predictive biomarker response platform in partnership with Divergence NeuroTech. Its biomarker platform is artificial intelligence and machine learning and prescribes suitable psychedelic treatments and provides real-time feedback during a psychedelic event, and informs the development of a post-therapy system of patient-specific support.
